Madrigal (MDGL) Reports Q4 Loss, Tops Revenue Estimates

Core Viewpoint - Madrigal (MDGL) reported a quarterly loss of $2.71 per share, significantly better than the Zacks Consensus Estimate of a loss of $4.12, indicating a positive earnings surprise of 34.22% [1] Financial Performance - The company posted revenues of $103.32 million for the quarter ended December 2024, surpassing the Zacks Consensus Estimate by 1.69%, compared to zero revenues a year ago [2] - Over the last four quarters, Madrigal has exceeded consensus EPS estimates three times [2] Stock Performance and Outlook - Madrigal shares have increased by approximately 0.3% since the beginning of the year, while the S&P 500 has gained 1.3% [3] - The current consensus EPS estimate for the upcoming quarter is -$3.17 on revenues of $106.02 million, and for the current fiscal year, it is -$12 on revenues of $536.23 million [7] Industry Context - The Medical - Drugs industry, to which Madrigal belongs, is currently in the top 50% of over 250 Zacks industries, suggesting a favorable outlook compared to the bottom 50% [8] - The performance of Madrigal's stock may be influenced by the overall industry outlook and trends in earnings estimate revisions [5][8]